Alaunos Therapeutics Inc (STU:WEK)
€ 1.66 0 (-4.82%) Market Cap: 338.23 Mil Enterprise Value: 276.94 Mil PE Ratio: 0 PB Ratio: 1.04 GF Score: 54/100

Q2 2019 ZIOPHARM Oncology Inc Earnings Call Transcript

Aug 08, 2019 / 12:30PM GMT
Release Date Price: €5.06 (-7.16%)
Operator

Good morning, ladies and gentlemen, and welcome to the Ziopharm Oncology's Second Quarter 2019 Earnings Call. (Operator Instructions) As a reminder, this conference call is being recorded.

I would now like to turn the conference over to your host, Mr. Chris Taylor, Vice President of Investor Relations and Corporate Communications. Sir, you may begin.

Christopher Taylor
ZIOPHARM Oncology, Inc. - VP of IR & Corporate Communications

Thank you, Bridget. Good morning, and welcome to the Ziopharm Oncology conference call and webcast to review results for the second quarter of 2019. This morning, we filed our 10-Q and issued our Q2 news release, both of which are available in the Investors section of our website, ziopharm.com.

During this call, the company will make a number of forward-looking statements, including statements regarding the potential therapeutic candidates in our development pipeline, regulatory status, financial information and business trends. Forward-looking statements are subject to numerous risks and uncertainties as

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot